BackgroundMucopolysaccharidosis VI (MPS VI), due to recessively inherited 4-sulfatase (4S) deficiency, results in lysosomal storage of dermatan sulfate in numerous tissues. Retinal involvement is limited to the retinal pigment epithelium (RPE). This study aimed to determine whether recombinant adeno-associated virus (AAV)-mediated delivery of 4S would reverse the RPE pathology seen in MPS VI cats.MethodsAAV.f4S, containing the feline 4S cDNA, was delivered unilaterally to eyes of affected cats by subretinal or intravitreal injection. Contralateral eyes received AAV with the green fluorescent protein (GFP) reporter gene as control. At 2-11 months post-injection, the cats were sacrificed and the treatment effects were evaluated histologically...
As a preliminary step toward muscle-mediated gene therapy in the mucopolysaccharidosis (MPS) type VI...
We hypothesize that recombinant feline immunodeficiency viral (rFIV) vectors may be useful for gene ...
International audiencePrevious studies have tested gene replacement therapy in RPE65-deficient dogs ...
Mucopolysaccharidosis type VI (MPS VI) is an autosomal recessive disease caused by a deficiency of N...
Mucopolysaccharidosis (MPS) VI is due to a deficiency in the activity of N-acetylgalactosamine 4-sul...
Fibroblast-mediated ex vivo gene therapy was evaluated in the N-acetylgalactosamine 4-sulfatase (4S)...
AbstractFibroblast-mediated ex vivo gene therapy was evaluated in the N-acetylgalactosamine 4-sulfat...
In a feline model of mucopolysaccharidosis type VI (MPS VI), recombinant feline N-acetylgalactosamin...
Mucopolysaccharidosis type VI (MPS VI) is a lysosomal storage disease caused by a deficiency of N-ac...
Three cats with feline arylsulfatase-B-deficient mucopolysaccharidosis were studied by light and tra...
We report studies that suggest enzyme replacement therapy will result in a significant reduction in ...
The cat is emerging as a promising large animal model for preclinical testing of retinal dystrophy t...
We report evidence of a dose responsive effect of enzyme replacement therapy in mucopolysaccharidosi...
This study evaluates the immunological response following weekly 2h infusions of recombinant human N...
Defects in the beta subunit of rod cGMP phosphodiesterase 6 (PDE6 beta) are associated with autosoma...
As a preliminary step toward muscle-mediated gene therapy in the mucopolysaccharidosis (MPS) type VI...
We hypothesize that recombinant feline immunodeficiency viral (rFIV) vectors may be useful for gene ...
International audiencePrevious studies have tested gene replacement therapy in RPE65-deficient dogs ...
Mucopolysaccharidosis type VI (MPS VI) is an autosomal recessive disease caused by a deficiency of N...
Mucopolysaccharidosis (MPS) VI is due to a deficiency in the activity of N-acetylgalactosamine 4-sul...
Fibroblast-mediated ex vivo gene therapy was evaluated in the N-acetylgalactosamine 4-sulfatase (4S)...
AbstractFibroblast-mediated ex vivo gene therapy was evaluated in the N-acetylgalactosamine 4-sulfat...
In a feline model of mucopolysaccharidosis type VI (MPS VI), recombinant feline N-acetylgalactosamin...
Mucopolysaccharidosis type VI (MPS VI) is a lysosomal storage disease caused by a deficiency of N-ac...
Three cats with feline arylsulfatase-B-deficient mucopolysaccharidosis were studied by light and tra...
We report studies that suggest enzyme replacement therapy will result in a significant reduction in ...
The cat is emerging as a promising large animal model for preclinical testing of retinal dystrophy t...
We report evidence of a dose responsive effect of enzyme replacement therapy in mucopolysaccharidosi...
This study evaluates the immunological response following weekly 2h infusions of recombinant human N...
Defects in the beta subunit of rod cGMP phosphodiesterase 6 (PDE6 beta) are associated with autosoma...
As a preliminary step toward muscle-mediated gene therapy in the mucopolysaccharidosis (MPS) type VI...
We hypothesize that recombinant feline immunodeficiency viral (rFIV) vectors may be useful for gene ...
International audiencePrevious studies have tested gene replacement therapy in RPE65-deficient dogs ...